Opinion

Video

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec—highlighting how each is administered, and share their impressions of the safety and efficacy of these agents.

Video content above is prompted by the following:

  • Three new treatments for patients who are unresponsive to BCG were FDA approved in the last 5 years. Briefly discuss each of the following approved therapies and how are they are administered.
  • Pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec
  • What are your impressions of the safety and efficacy of these agents?
Related Videos
1 expert in this video
1 expert in this video
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.